Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Passes Above 200 Day Moving Average – Time to Sell?

Shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.84 and traded as high as $3.75. Sonoma Pharmaceuticals shares last traded at $3.25, with a volume of 270,634 shares trading hands.

Sonoma Pharmaceuticals Price Performance

The business has a 50-day simple moving average of $2.67 and a 200-day simple moving average of $2.85. The firm has a market capitalization of $5.85 million, a PE ratio of -0.90 and a beta of 1.56.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its quarterly earnings data on Wednesday, February 5th. The company reported ($0.59) earnings per share (EPS) for the quarter. Sonoma Pharmaceuticals had a negative net margin of 26.82% and a negative return on equity of 68.98%. On average, research analysts expect that Sonoma Pharmaceuticals, Inc. will post -0.67 earnings per share for the current year.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.